companiesandmarkets.com

Return to Report | Print

Poniard Pharmaceuticals Inc - Premium Company Profile

http://www.companiesandmarkets.com/Summary-Company-Profile/poniard-pharmaceuticals-inc-premium-company-profile-42823.asp

Report Summary

Introduction

Poniard Pharmaceuticals, formerly known as NeoRx Corporation, is a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapy products. The company’s lead product candidate, Picoplatin, is currently in Phase III clinical development for small cell lung cancer and offers a huge opportunity for the company to achieve its first commercial success.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Highlights

    The company’s product pipeline includes single product, Picoplatin, a new generation cytotoxic platinum compound that provides a differentiated spectrum of activity and an improved safety profile. Picoplatin is being developed for small cell lung cancer (Phase III), colorectal cancer (Phase II), and prostate cancer (Phase II).

    The company does not have any significant ongoing revenue sources till date. On occasion, the company derives revenues from the sale or licensing of its patented technologies and from government grants.

    The company’s total revenues decreased from $11.1 million in 2002 to absolute zero in 2006. For the fiscal 2006, the company did not recognize any revenues due to non-recognition of any royalties for licensed intellectual property as recognized in 2004 and 2005 from Boston Scientific.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Overview 1
    Catalyst 1
    Summary 1
    Table of Contents 2
    Table of figures 3
    Table of tables 4
    Company Structure 5
    Company Overview and Key Facts 5
    Business Description 6
    Landmark Products and Services 6
    Picoplatin 6
    History 7
    Locations and Subsidiaries 8
    Company Financials 9
    Stock Market Performance 9
    P&L 11
    Balance Sheet 14
    Cash Flow 14
    Products & Services 15
    Pipeline Products 15
    In-house Pipeline 15
    Picoplatin 15
    AC Forecast Product Sales 16
    Competitors and Strategic Business Relationships 17
    Key Competitors 17
    Key Suppliers 17
    Shareholding Structure 18
    Strategy 19
    Company View 19
    Corporate Strategy 22
    SWOT Analysis 23
    Overview 23
    Strengths 24
    Picoplatin for small cell lung cancer 24
    Weaknesses 25
    Discontinued product candidates 25
    Termination of agreement with Janssen Pharmaceutica 25
    Opportunities 26
    Market for anti-cancer drugs 26
    Threats 27
    Uncertainty in the coverage and reimbursement status 27
    Lengthy and expensive regulatory process 27
    Value Chain Analysis 28
    Overview 28
    Discovery and Product Development 28
    Scorecard 29
    Overview 29
    Scorecard Analysis 29
    Key Employees 30
    List of Key Employees 30
    Key Employee Biographies 31
    Jerry McMahon 31
    Ronald A Martell 31
    Robert S Basso 32
    Frederick B Craves 32
    E Rolland Dickson 33
    Carl S Goldfischer 33
    Robert M Littauer 34
    Nicholas J Simon 34
    David R Stevens 35
    Caroline M Loewy 35
    Robert De Jager 36
    David A Karlin 36
    Cheni Kwok 37
    Anna Lewak Wight 37
    Financial and Operational Overview 38
    Financial and Operational Overview 38
    APPENDIX 40
    Ask the analyst 40
    Datamonitor consulting 40
    Disclaimer 40
    List of Tables
    Table 1: Poniard - Key Facts 5
    Table 2: Poniard - Locations and Subsidiaries 8
    Table 3: Poniard - Year-End Share Price and Market Capitalization, 2002-2006 ($) 9
    Table 4: Poniard - Key Events Impacting Share Price Performance 10
    Table 5: Poniard - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11
    Table 6: Poniard - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 13
    Table 7: Poniard - Balance Sheet, 2002-2006 ($ Mn) 14
    Table 8: Poniard - Cash Flow, 2002-2006 ($ Mn) 14
    Table 9: Poniard - In-house Pipeline Products 15
    Table 10: Poniard - Forecast Sales, 2006-2010 ($ Mn) 16
    Table 11: Poniard - Key Competitors 17
    Table 12: Poniard - Key Suppliers 17
    Table 13: Poniard - Key Shareholders 18
    Table 14: Poniard - SWOT Analysis Summary 23
    Table 15: Poniard - Value Chain Analysis 28
    Table 16: Poniard - Key Employees 30
    Table 17: Poniard - Financial and Operational Overview 38
    List of Figures
    Figure 1: Poniard - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12